BiotechTube

lovastatin

Phase 2/3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
65
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atherosclerosis

Conditions

Atherosclerosis, Coronary Artery Disease

Trial Timeline

Jun 1, 1985 โ†’ Feb 1, 1992

NCT ID
NCT00116870

About lovastatin

lovastatin is a phase 2/3 stage product being developed by Merck for Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00116870. Target conditions include Atherosclerosis, Coronary Artery Disease.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT00116870Phase 2/3Completed

Competing Products

20 competing products in Atherosclerosis

See all competitors
ProductCompanyStageHype Score
Orforglipron + PlaceboEli LillyPhase 3
77
Olmesartan medoxomil + PlaceboDaiichi SankyoPhase 3
77
Pactimibe sulfateDaiichi SankyoPhase 2/3
65
PactimibeDaiichi SankyoPhase 2
52
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPhase 3
77
Micronized 17B-estradiolJohnson & JohnsonPhase 2/3
65
Rosuvastatin + placebo + aspirin + placeboAstraZenecaApproved
85
Rosuvastatin + PlaceboAstraZenecaApproved
85
rosuvastatin + placeboAstraZenecaPhase 1
33
Rosuvastatin + PlaceboAstraZenecaPhase 1
33
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
77
Rosuvastatin + PlaceboAstraZenecaPhase 3
77
Rosuvastatin (5mg๏ผŒ10mg๏ผŒ20mg) + Rosuvastatin 5mgAstraZenecaApproved
85
Vorapaxar + PlaceboMerckPhase 3
77
Vorapaxar + Placebo + Aspirin + ClopidogrelMerckPhase 2
52
Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved
85
Ezetimibe + PlaceboMerckApproved
85
Vorapaxar + PlaceboMerckPhase 3
77
NiaspanMerckPre-clinical
23
MK0633MerckPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
MavencladยฎApproved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85